What Happened
- The US Food and Drug Administration (FDA) released draft guidance on 23 February 2026 establishing a new "Plausible Mechanism Framework" for approving individualised therapies targeting ultra-rare diseases.
- The framework creates a novel regulatory pathway through which cutting-edge treatments tailor-made for single patients or very small patient populations can receive full FDA approval without the need for conventional randomised controlled trials (RCTs), which are often impossible when only a handful of patients worldwide share a condition.
- The draft guidance explicitly covers genome editing technologies (such as CRISPR) and RNA-based therapies such as antisense oligonucleotides, while remaining open to additional tailored therapeutics.
- Key approval criteria include: identifying the specific disease-causing genetic abnormality, demonstrating the therapy targets the root cause or proximate biological pathway, leveraging well-characterised natural history data from untreated patients, and confirming successful target engagement or gene editing.
- The FDA opened a 60-day public comment period before beginning to finalise the guidance.
Static Topic Bridges
The US FDA and Drug Regulation
The US Food and Drug Administration (FDA) is the federal agency under the Department of Health and Human Services responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs, biological products, and medical devices. Drug approval in the US ordinarily requires clinical trials across three phases demonstrating safety and efficacy, a process that can take over a decade and cost billions of dollars. For rare diseases, this traditional pathway is often impractical because insufficient patient populations exist to power statistically robust trials.
- The FDA's standard approval route requires substantial evidence of effectiveness, typically from two adequate and well-controlled trials.
- Accelerated and Breakthrough Designation pathways were introduced to speed up approval for serious conditions — the new Plausible Mechanism Framework extends this logic further to ultra-rare, single-patient scenarios.
- India's drug regulator — the Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health — often follows FDA approvals for rare disease drugs as a reference point.
Connection to this news: The new framework represents the FDA's most significant departure yet from trial-based evidence, acknowledging that for some ultra-rare conditions, mechanistic plausibility and target engagement data may be the best available — and sufficient — evidence of efficacy.
The Orphan Drug Act, 1983 (USA) and Rare Disease Policy
Passed by the US Congress in 1983, the Orphan Drug Act (ODA) incentivised pharmaceutical companies to develop drugs for rare diseases by offering tax credits, waiver of prescription drug user fees, and a seven-year period of market exclusivity. The Act defines a rare disease as one affecting fewer than 200,000 persons in the United States (or where cost recovery is not reasonably expected regardless of patient numbers). Prior to the ODA, fewer than 10 orphan drugs had been approved in the US; as of recent years, hundreds have been developed under the Act's incentive structure.
- The EU counterpart is the EU Orphan Regulation (Regulation (EC) 141/2000), offering 10 years of market exclusivity.
- India does not have a dedicated orphan drug policy, though the National Policy for Rare Diseases (2021) provides a one-time financial assistance of ₹50 lakh for treatment of patients with rare diseases listed under its framework.
- Approximately 7,000 rare diseases are known; about 95% still lack approved treatments.
Connection to this news: The FDA's new framework builds on the Orphan Drug Act's foundational premise — that standard commercial development models cannot serve ultra-rare disease patients — by extending this logic into the personalised/gene-editing era.
CRISPR and Personalised Gene Therapy
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing technology that enables precise modifications to DNA within living cells. Using a guide RNA that directs the CRISPR-associated enzyme (typically Cas9) to a specific genomic location, researchers can cut, correct, delete, or insert genetic sequences. In personalised applications, a therapy is designed specifically for one patient's unique mutation. A landmark proof-of-concept occurred at Children's Hospital of Philadelphia, where a CRISPR-based base-editing therapy developed in just six months successfully treated an infant with severe CPS1 deficiency, a life-threatening metabolic disorder.
- Base editing — a refined CRISPR variant — corrects single DNA "letter" mismatches without creating double-strand DNA breaks, reducing off-target editing risk.
- RNA-based therapies such as antisense oligonucleotides (ASOs) work differently: they bind to messenger RNA to suppress, restore, or modify gene expression without altering the underlying DNA.
- Both technologies are specifically mentioned in the FDA's new Plausible Mechanism Framework guidance.
- India's Department of Biotechnology (DBT) is actively investing in gene therapy research under the National Biopharma Mission.
Connection to this news: The FDA's framework directly addresses the regulatory vacuum that has existed for personalised CRISPR and ASO therapies — treatments so individualised that traditional clinical trial designs are structurally unsuitable.
Key Facts & Data
- FDA's Plausible Mechanism Framework draft guidance released: 23 February 2026
- Comment period: 60 days
- Rare disease definition (US): affects fewer than 200,000 people in the US
- Orphan Drug Act (ODA) enacted: 1983; incentives include 7-year market exclusivity and tax credits
- ~7,000 rare diseases known globally; ~95% have no approved treatment
- India's National Policy for Rare Diseases (2021): one-time assistance of ₹50 lakh per patient
- First personalised CRISPR therapy (CHOP, KJ case): developed and delivered in ~6 months
- India's CDSCO is the national drug regulator (Ministry of Health and Family Welfare)